Rajarshi Keshav, Chatterjee Aroni, Ray Shashikant
School of Community Science and Technology (SOCSAT) Indian Institute of Engineering Scince and Technology (IIEST), Shibpur, Howrah, West Bengal 711103, India.
Indian Council of Medical Research (ICMR)-Virus Research Laboratory, NICED, Kolkata, India.
Med Drug Discov. 2020 Sep;7:100049. doi: 10.1016/j.medidd.2020.100049. Epub 2020 May 26.
The Bacillus Calmette-Guerin vaccine (BCG vaccine) designed to prevent tuberculosis in children has been shown to induce a adaptive immune response in the body to fight against bacteria as well as other parasites and viruses. This knowledge has been reciprocated to generate the idea that this vaccine can also offer protection against severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). Some recent pre-print articles have highlighted that countries with mass BCG immunizations seems to have a lower incidence of coronavirus disease 2019 (COVID-19) compared to those without BCG immunization. There are yet no experimental proof of any such association and the world health organisation (WHO) is currently testing the theory with clinical trials on selected cohorts. Epidemiologists and other scientific experts has expressed both their hope and concern simultaneously regarding the success theory of BCG vaccination to prevent COVID-19. Though its still not verified in any way whether the BCG vaccination can actually prevent COVID-19 or not but we believe a thorough analytical research in this regard is indeed worth a shot.
旨在预防儿童结核病的卡介苗(BCG疫苗)已被证明能在体内诱导适应性免疫反应,以对抗细菌以及其他寄生虫和病毒。基于这一认知,人们由此产生了一种想法,即这种疫苗也可以提供针对严重急性呼吸综合征冠状病毒2(SARS-COV-2)的保护。最近的一些预印本文章强调,与未进行卡介苗大规模接种的国家相比,进行卡介苗大规模接种的国家2019冠状病毒病(COVID-19)的发病率似乎较低。目前尚无任何此类关联的实验证据,世界卫生组织(WHO)正在通过对选定队列进行临床试验来验证这一理论。流行病学家和其他科学专家对卡介苗接种预防COVID-19这一理论的成功既表达了希望,也表达了担忧。尽管目前仍未以任何方式证实卡介苗接种是否真的能预防COVID-19,但我们认为在这方面进行深入的分析研究确实值得一试。